Abstract
Aims: Posterior Urethral Valve (PUV) is a common congenital urethral obstruction leading to significant morbidity. Despite successful fulguration of posterior urethral valve, the bladder dysfunction persists in most of the cases. Oxybutynin, an anticholinergic drug is commonly used to manage this bladder dysfunction. This study aimed to assess the impact of oxybutynin on bladder and urinary tract function in children with valve fulguration. Methods: A retrospective observational study was conducted on 41 children who underwent PUV fulguration at a tertiary care center in Bangladesh between 2020 and 2023. All subjects received oxybutynin for at least 6 months post-fulguration. Bladder wall morphology, hydronephrosis, vesicoureteral reflux (VUR), and post void residues (PVR) were assessed. Side effects of oxybutynin were also documented. Results: All patients had bilateral hydroureteronephrosis (HUN), except one, who was with unilateral HUN during primary diagnosis. Complete resolution of bilateral HUN was seen in Renal USG 14 patients at 6 months post fulguration. Correction of VUR documented in 13 units out of 32 units. Mean serum creatinine decreased to 0.52 ± 0.22from 0.73 ± 0.52 within 6 months of fulguration. Four patients exhibited significant PVR, leading to clean intermittent catheterization (CIC) initiation. Conclusion: Combined with PUV fulguration and oxybutynin therapy appears to be effective in improving bladder function. Further prospective studies incorporating urodynamic evaluations are warranted to validate these findings.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call